৳ 5,500/unit
Pack: ৳ 5,500
৳ 5,500/unit
Pack: ৳ 5,500
At a glance
Ruxolitinib is a JAK1/JAK2 inhibitor used for the treatment of myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease (GVHD). It modulates hematopoiesis and immune function by inhibiting JAK-STAT signaling pathways.
Indications
- Intermediate or high-risk myelofibrosis (primary MF, post-polycythemia vera MF, post-essential thrombocythemia MF)
- Polycythemia vera (inadequate response or intolerance to hydroxyurea)
- Steroid-refractory acute graft-versus-host disease (GVHD) – adults and pediatric patients ≥12 years
Pharmacology
Ruxolitinib inhibits JAK1 and JAK2 kinases, blocking JAK-STAT signaling pathways. It prevents STAT phosphorylation and nuclear translocation, modulating gene expression. In myelofibrosis, it reduces splenomegaly, decreases JAK2V617F mutant cells, and reduces inflammatory cytokines (TNF-α, IL-6).
Dosage
Adult Dose (Oral):
Myelofibrosis (based on platelet count):
- >200 × 10⁹/L: 20 mg twice daily
- 100-200 × 10⁹/L: 15 mg twice daily
- 50-100 × 10⁹/L: 5 mg twice daily
Polycythemia Vera:
- Starting: 10 mg twice daily
Acute GVHD:
- Starting: 5 mg twice daily; increase to 10 mg twice daily after 3 days if ANC/platelets not decreased by ≥50%
Side effects
Common Side Effects:
- Thrombocytopenia
- Anemia
- Neutropenia
- Risk of infection
- Bruising
- Dizziness and headache
- Non-melanoma skin cancer
- Lipid elevations
Use in pregnancy
Use in Pregnancy: No adequate controlled studies; use only if clearly needed; consult your doctor.
Pregnancy Category: C — always consult a doctor before taking during pregnancy.
Precautions & warnings
- Thrombocytopenia, anemia, neutropenia: Reduce dose or interrupt; monitor CBC every 2-4 weeks
- Risk of serious bacterial, mycobacterial, fungal, and viral infections
- Tuberculosis: Evaluate risk before starting; delay if active TB
- PML: Suspect, discontinue and evaluate
- Herpes zoster: Early signs and symptoms, seek treatment
- Hepatitis B: Monitor HBV-DNA titers
- Do not stop abruptly (withdrawal syndrome); taper gradually
- Non-melanoma skin cancer: Periodic skin examinations
- Lipids: Assess at 8-12 weeks
Overdose effects
No specific antidote for overdose; single doses up to 200 mg are tolerable; higher doses cause myelosuppression; hemodialysis is not effective.
Storage conditions
Store below 30°C in a dry place, away from sunlight; keep out of reach of children.